Published in J Exp Med on May 01, 1994
Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells. J Exp Med (1996) 6.08
Lung epithelial cells are a major site of murine gammaherpesvirus persistence. J Exp Med (1998) 3.45
B cells regulate murine gammaherpesvirus 68 latency. J Virol (1999) 2.79
Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev (2009) 2.75
Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med (1998) 2.60
Interferon gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J Exp Med (1998) 2.04
Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcgamma receptor homologs. J Virol (2002) 1.92
Latency, without persistence, of murine cytomegalovirus in the spleen and kidney. J Virol (1995) 1.91
The immunoevasive function encoded by the mouse cytomegalovirus gene m152 protects the virus against T cell control in vivo. J Exp Med (1999) 1.88
Kinetic analysis of the specific host response to a murine gammaherpesvirus. J Virol (1998) 1.82
Focal transcriptional activity of murine cytomegalovirus during latency in the lungs. J Virol (1999) 1.59
Cutting edge: murine cytomegalovirus induces a polyfunctional CD4 T cell response. J Immunol (2008) 1.50
Oligoclonal bands in multiple sclerosis reactive against two herpesviruses and association with magnetic resonance imaging findings. Mult Scler (2013) 1.45
Virus attenuation after deletion of the cytomegalovirus Fc receptor gene is not due to antibody control. J Virol (1998) 1.44
Alpha/beta interferons regulate murine gammaherpesvirus latent gene expression and reactivation from latency. J Virol (2005) 1.35
Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells. J Virol (2003) 1.35
Patchwork pattern of transcriptional reactivation in the lungs indicates sequential checkpoints in the transition from murine cytomegalovirus latency to recurrence. J Virol (1999) 1.32
Cytotoxic T-lymphocyte responses to cytomegalovirus in normal and simian immunodeficiency virus-infected rhesus macaques. J Virol (1996) 1.31
The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60. J Exp Med (2006) 1.27
Identification and expression of a murine cytomegalovirus early gene coding for an Fc receptor. J Virol (1994) 1.24
Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus. J Virol (2002) 1.23
Feeling manipulated: cytomegalovirus immune manipulation. Virol J (2009) 1.19
Direct relationship between suppression of virus-specific immunity and emergence of cytomegalovirus disease in simian AIDS. J Virol (2003) 1.19
Vigorous innate and virus-specific cytotoxic T-lymphocyte responses to murine cytomegalovirus in the submaxillary salivary gland. J Virol (2003) 1.18
CD4+ T cell help has an epitope-dependent impact on CD8+ T cell memory inflation during murine cytomegalovirus infection. J Immunol (2009) 1.15
Attenuation of innate immunity by cytomegalovirus IL-10 establishes a long-term deficit of adaptive antiviral immunity. Proc Natl Acad Sci U S A (2010) 1.12
MHC class I immune evasion in MCMV infection. Med Microbiol Immunol (2008) 1.10
Strain-specific neutralization of human cytomegalovirus isolates by human sera. J Virol (1999) 1.05
Mucosal and parenteral vaccination against acute and latent murine cytomegalovirus (MCMV) infection by using an attenuated MCMV mutant. J Virol (1998) 1.05
Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties. J Clin Invest (2010) 1.04
Absence of cross-presenting cells in the salivary gland and viral immune evasion confine cytomegalovirus immune control to effector CD4 T cells. PLoS Pathog (2011) 1.00
Human cytomegalovirus Fcγ binding proteins gp34 and gp68 antagonize Fcγ receptors I, II and III. PLoS Pathog (2014) 1.00
Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice. J Virol (2008) 0.99
Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy. J Virol (2007) 0.98
A spread-deficient cytomegalovirus for assessment of first-target cells in vaccination. J Virol (2010) 0.96
CD8+ T lymphocytes control murine cytomegalovirus replication in the central nervous system of newborn animals. J Immunol (2008) 0.95
T cell responses to cytomegalovirus. Nat Rev Immunol (2016) 0.95
Murine cytomegalovirus regulation of NKG2D ligands. Med Microbiol Immunol (2008) 0.95
Role of antibodies in controlling viral disease: lessons from experiments of nature and gene knockouts. J Virol (2000) 0.92
Viral escape mechanisms--escapology taught by viruses. Int J Exp Pathol (2001) 0.89
B7-mediated costimulation of CD4 T cells constrains cytomegalovirus persistence. J Virol (2010) 0.89
Interleukin-12 exhibits potent antiviral activity in experimental herpesvirus infections. J Virol (1997) 0.88
The tiers and dimensions of evasion of the type I interferon response by human cytomegalovirus. J Mol Biol (2013) 0.87
Persistent humoral immune responses in the CNS limit recovery of reactivated murine cytomegalovirus. PLoS One (2012) 0.86
CD28/B7-mediated co-stimulation is critical for early control of murine cytomegalovirus infection. Viral Immunol (2009) 0.85
Control of murine cytomegalovirus infection by γδ T cells. PLoS Pathog (2015) 0.85
Immunobiology of congenital cytomegalovirus infection of the central nervous system—the murine cytomegalovirus model. Cell Mol Immunol (2014) 0.85
CMV-encoded Fcγ receptors: modulators at the interface of innate and adaptive immunity. Semin Immunopathol (2014) 0.84
Polyclonal cytomegalovirus-specific antibodies not only prevent virus dissemination from the portal of entry but also inhibit focal virus spread within target tissues. Med Microbiol Immunol (2008) 0.83
Memory T cells specific for murine cytomegalovirus re-emerge after multiple challenges and recapitulate immunity in various adoptive transfer scenarios. J Immunol (2015) 0.83
New tools to study the role of B cells in cytomegalovirus infections. Med Microbiol Immunol (2008) 0.83
Transmission of murine cytomegalovirus in breast milk: a model of natural infection in neonates. J Virol (2011) 0.82
Immunity to cytomegalovirus in early life. Front Immunol (2014) 0.81
The mouse cytomegalovirus immediate-early 1 gene is not required for establishment of latency or for reactivation in the lungs. J Virol (2009) 0.81
A flow cytometry-based method for detecting antibody responses to murine cytomegalovirus infection. J Virol Methods (2007) 0.81
Deciphering the role of DC subsets in MCMV infection to better understand immune protection against viral infections. Front Microbiol (2014) 0.81
T cell memory in the context of persistent herpes viral infections. Viruses (2012) 0.80
Blood and alveolar lymphocyte subsets in pulmonary cytomegalovirus infection after lung transplantation. BMC Infect Dis (2001) 0.79
Chronic lymphocytic leukemia patients have a preserved cytomegalovirus-specific antibody response despite progressive hypogammaglobulinemia. PLoS One (2013) 0.78
Antiviral antibodies are necessary to prevent cytotoxic T-lymphocyte escape in mice infected with a coronavirus. J Virol (2007) 0.78
The role of neutralizing antibodies for mouse mammary tumor virus transmission and mammary cancer development. Proc Natl Acad Sci U S A (2002) 0.78
Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity. Comp Med (2008) 0.78
Tracking the fate of antigen-specific versus cytokine-activated natural killer cells after cytomegalovirus infection. J Exp Med (2016) 0.78
Exploitation of herpesviral transactivation allows quantitative reporter gene-based assessment of virus entry and neutralization. PLoS One (2011) 0.77
Viral Persistence Induces Antibody Inflation without Altering Antibody Avidity. J Virol (2016) 0.77
CD4 T cell responses in latent and chronic viral infections. Front Immunol (2013) 0.77
Rat Cytomegalovirus Vaccine Prevents Accelerated Chronic Rejection in CMV-Naïve Recipients of Infected Donor Allograft Hearts. Am J Transplant (2015) 0.76
Passive immunization with neutralizing antibodies interrupts the mouse mammary tumor virus life cycle. J Virol (2003) 0.75
Natural killer cells in herpesvirus infections. F1000Res (2017) 0.75
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus. PLoS Pathog (2017) 0.75
A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature (1991) 13.19
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature (1985) 9.62
Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science (1992) 7.04
Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol (1985) 4.76
CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol (1987) 4.58
Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes. J Exp Med (1989) 2.89
The NK-1.1(-) mouse: a model to study differentiation of murine NK cells. J Immunol (1986) 2.48
A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. J Virol (1988) 2.34
The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med (1994) 2.26
Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol (1993) 2.04
Cellular and molecular basis of the protective immune response to cytomegalovirus infection. Curr Top Microbiol Immunol (1990) 2.00
Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes. J Virol (1990) 1.99
In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection. J Exp Med (1987) 1.58
Participation of endogenous tumour necrosis factor alpha in host resistance to cytomegalovirus infection. J Gen Virol (1993) 1.51
Modification by adoptive humoral immunity of murine cytomegalovirus infection. J Infect Dis (1981) 1.43
Indirect double sandwich ELISA for the specific and quantitative measurement of mouse IgM, IgA and IgG subclasses. J Immunol Methods (1989) 1.27
Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies. J Gen Virol (1991) 1.10
Immune response to human cytomegalovirus infection. Curr Top Microbiol Immunol (1990) 1.03
Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci U S A (1997) 5.37
Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol (1999) 4.84
Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol (1985) 4.76
CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol (1987) 4.58
Systematic excision of vector sequences from the BAC-cloned herpesvirus genome during virus reconstitution. J Virol (1999) 4.23
Cloning and mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial artificial chromosome. J Virol (2000) 4.09
Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes. J Virol (2000) 3.35
Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection. Nature (1984) 3.26
Molecular cloning and physical mapping of murine cytomegalovirus DNA. J Virol (1983) 3.11
Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell (1991) 2.99
Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes. J Exp Med (1989) 2.89
Sequence and structural organization of murine cytomegalovirus immediate-early gene 1. J Virol (1987) 2.84
A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. Nature (1989) 2.76
Immune evasion by cytomegalovirus--survival strategies of a highly adapted opportunist. Trends Microbiol (1998) 2.75
Viral mechanisms of immune evasion. Immunol Today (2000) 2.74
A long and complex enhancer activates transcription of the gene coding for the highly abundant immediate early mRNA in murine cytomegalovirus. Proc Natl Acad Sci U S A (1985) 2.74
A ribonucleotide reductase homolog of cytomegalovirus and endothelial cell tropism. Science (2001) 2.70
Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands. J Virol (1992) 2.67
Temporal regulation of murine cytomegalovirus transcription and mapping of viral RNA synthesized at immediate early times after infection. J Virol (1984) 2.62
Rapid identification of essential and nonessential herpesvirus genes by direct transposon mutagenesis. Nat Biotechnol (1999) 2.61
Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med (1998) 2.60
A mouse cytomegalovirus glycoprotein retains MHC class I complexes in the ERGIC/cis-Golgi compartments. Immunity (1997) 2.49
A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity (1997) 2.45
The cytolytic T lymphocyte response to the murine cytomegalovirus. II. Detection of virus replication stage-specific antigens by separate populations of in vivo active cytolytic T lymphocyte precursors. Eur J Immunol (1984) 2.44
Characterization of the major immediate-early polypeptides encoded by murine cytomegalovirus. J Virol (1985) 2.41
A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. J Virol (1988) 2.34
A role for the proteasome regulator PA28alpha in antigen presentation. Nature (1996) 2.30
Immediate-early genes of murine cytomegalovirus: location, transcripts, and translation products. J Virol (1987) 2.30
A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation. EMBO J (1999) 2.30
Cytomegalovirus prevents antigen presentation by blocking the transport of peptide-loaded major histocompatibility complex class I molecules into the medial-Golgi compartment. J Exp Med (1992) 2.29
The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med (1994) 2.26
Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J Exp Med (1994) 2.13
K3-mediated evasion of CD8(+) T cells aids amplification of a latent gamma-herpesvirus. Nat Immunol (2002) 2.13
The 89,000-Mr murine cytomegalovirus immediate-early protein activates gene transcription. J Virol (1986) 2.08
Structural organization, expression, and functional characterization of the murine cytomegalovirus immediate-early gene 3. J Virol (1992) 2.08
Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes. J Virol (1990) 1.99
A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface. EMBO J (1997) 1.98
Molecular basis for cytolytic T-lymphocyte recognition of the murine cytomegalovirus immediate-early protein pp89. J Virol (1988) 1.97
Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol (1991) 1.96
Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-gamma and tumour necrosis factor. J Gen Virol (1994) 1.89
The immunoevasive function encoded by the mouse cytomegalovirus gene m152 protects the virus against T cell control in vivo. J Exp Med (1999) 1.88
Cloned long-term cytolytic T-lymphocyte line with specificity for an immediate-early membrane antigen of murine cytomegalovirus. J Virol (1986) 1.86
Viral mechanisms of immune evasion. Trends Microbiol (2000) 1.85
Identification of the mouse cytomegalovirus genomic region affecting major histocompatibility complex class I molecule transport. J Virol (1995) 1.77
Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell (1996) 1.76
Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape. J Virol (1994) 1.71
Forward with BACs: new tools for herpesvirus genomics. Trends Genet (2000) 1.66
Presentation of CMV immediate-early antigen to cytolytic T lymphocytes is selectively prevented by viral genes expressed in the early phase. Cell (1989) 1.64
The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase. J Virol (1996) 1.63
Recognition of viral glycoproteins by influenza A-specific cross-reactive cytolytic T lymphocytes. J Exp Med (1980) 1.58
In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection. J Exp Med (1987) 1.58
Cytolytic T lymphocyte recognition of the murine cytomegalovirus nonstructural immediate-early protein pp89 expressed by recombinant vaccinia virus. J Exp Med (1987) 1.57
Enhancer requirement for murine cytomegalovirus growth and genetic complementation by the human cytomegalovirus enhancer. J Virol (1998) 1.56
A nonstructural polypeptide encoded by immediate-early transcription unit 1 of murine cytomegalovirus is recognized by cytolytic T lymphocytes. J Exp Med (1987) 1.52
The multiple immune-evasion genes of murine cytomegalovirus are not redundant: m4 and m152 inhibit antigen presentation in a complementary and cooperative fashion. J Exp Med (2001) 1.52
Participation of endogenous tumour necrosis factor alpha in host resistance to cytomegalovirus infection. J Gen Virol (1993) 1.51
Late-phase expression of a murine cytomegalovirus immediate-early antigen recognized by cytolytic T lymphocytes. J Virol (1986) 1.48
Host immune response to cytomegalovirus: products of transfected viral immediate-early genes are recognized by cloned cytolytic T lymphocytes. J Virol (1987) 1.47
Identification of the murine cytomegalovirus glycoprotein B gene and its expression by recombinant vaccinia virus. J Virol (1992) 1.46
Alloreactive cytotoxic T lymphocytes generated in the presence of viral-derived peptides show exquisite peptide and MHC specificity. J Immunol (1993) 1.45
Characterization of the murine cytomegalovirus early transcription unit e1 that is induced by immediate-early proteins. J Virol (1990) 1.45
Virus attenuation after deletion of the cytomegalovirus Fc receptor gene is not due to antibody control. J Virol (1998) 1.44
Cytomegaloviral control of MHC class I function in the mouse. Immunol Rev (1999) 1.42
Simultaneous expression of CD4 and CD8 antigens by a substantial proportion of resting porcine T lymphocytes. Eur J Immunol (1987) 1.41
Interference with antigen processing by viruses. Curr Opin Immunol (1997) 1.40
Structure and expression of murine cytomegalovirus immediate-early gene 2. J Virol (1991) 1.37
Failure in generating hemopoietic stem cells is the primary cause of death from cytomegalovirus disease in the immunocompromised host. J Exp Med (1988) 1.34
Lack of MHC class I complex expression has no effect on spread and control of cytomegalovirus infection in vivo. J Gen Virol (1996) 1.33
A mouse model for cytomegalovirus infection. Curr Protoc Immunol (2001) 1.32
Monoclonal antibodies reactive with swine lymphocytes. I. Antibodies to membrane structures that define the cytolytic T lymphocyte subset in the swine. J Immunol (1984) 1.29
The luminal part of the murine cytomegalovirus glycoprotein gp40 catalyzes the retention of MHC class I molecules. EMBO J (2000) 1.28
Identification and expression of a murine cytomegalovirus early gene coding for an Fc receptor. J Virol (1994) 1.24
The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med (1998) 1.22
The murine cytomegalovirus immune evasion protein m4/gp34 forms biochemically distinct complexes with class I MHC at the cell surface and in a pre-Golgi compartment. J Immunol (2001) 1.19
The cleavage preference of the proteasome governs the yield of antigenic peptides. J Exp Med (1995) 1.19
Development of bovine herpesvirus 4 as an expression vector using bacterial artificial chromosome cloning. J Gen Virol (2005) 1.17